Alembic Pharma reports 35% rise in net profit to Rs 333 cr for Sept quarter

Drug firm Alembic Pharmaceuticals on Thursday reported a 35.36 per cent rise in consolidated net profit to Rs 333.37 crore for the quarter ended September, mainly on account of robust sales.

The company had posted a net profit of Rs 246.27 crore for the corresponding period of the previous fiscal, Alembic Pharma said in a filing to BSE.

Consolidated revenue from operations stood at Rs 1,457.10 crore for the quarter under consideration. It was Rs 1,240.87 crore for the same period a year ago, it added.

"It was a strong quarter for the company led by growth in the domestic business. The International as well as API Business also continued to perform well," Alembic Pharmaceuticals MD Pranav Amin said.

Shares of Alembic Pharmaceuticals ended at Rs1,011.60on BSE, up 1.46 per cent from its previous close.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel